Interferon-λ3/4 genetic variants and interferon-λ3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese

被引:33
作者
Chen, Ji-Yih [1 ]
Wang, Chin-Man [2 ]
Chen, Tai-Di [3 ]
Wu, Yeong-Jian Jan [1 ]
Lin, Jing-Chi [1 ]
Lu, Ling Ying [4 ]
Wu, Jianming [5 ]
机构
[1] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Div Allergy Immunol & Rheumatol,Dept Med, 5 Fu Shin St, Taoyuan, Taiwan
[2] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Rehabil, 5 Fu Shin St, Taoyuan, Taiwan
[3] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Anat Pathol, Taoyuan, Taiwan
[4] Kaohsiung Vet Gen Hosp, Div Allergy Immunol & Rheumatol, Dept Med, 386 Dazhong 1st Rd, Kaohsiung 81362, Taiwan
[5] Univ Minnesota, Dept Med, Dept Vet & Biomed Sci, 235B Anim Sci Vet Med Bldg,1988 Fitch Ave, St Paul, MN 55108 USA
关键词
Interferon lambda; Lupus nephritis; Systemic lupus erythematosus; HEPATITIS-C VIRUS; GENOME-WIDE ASSOCIATION; III INTERFERONS; I INTERFERON; SPONTANEOUS CLEARANCE; AUTOIMMUNE-DISEASES; RIBAVIRIN THERAPY; ERYTHEMATOSUS; IL28B; LAMBDA;
D O I
10.1186/s13075-018-1683-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Type III interferons (IFNs) or IFN-lambda s are the newly discovered cytokines that primarily target the cells of epithelial and myeloid lineages, which are major components of kidneys. The current study aimed to investigate whether IFN-lambda s are involved in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis. Methods: TaqMan allele discrimination assays were used to determine IFNL3/4 SNP genotypes of 1620 healthy controls and 1013 SLE patients (two independent cohorts consisting of 831 and 182 subjects, respectively) from Taiwan. The distributions of IFNL3/4 SNP genotypes and allele frequencies were compared between SLE patients and healthy controls and among SLE patients stratified by clinical phenotypes. ELISA was used to determine the serum IFN-lambda 3 concentrations of SLE patients. Results: All major IFN3/4 SNP alleles were significantly associated with the risk for lupus nephritis (rs8099917T, P-FDR = 0.0021, OR 1.75, 95% CI 1.24-2.47; rs12979860C, P-FDR = 0.0034, OR 1.65, 95% CI 1.18-2.30; rs4803217C, P-FDR = 0.0021, OR 1.76, 95% CI 1.25-2.48; and ss469415590TT, P-FDR = 0.0021, OR 1.73, 95% CI 1.23-2.42) among SLE patients. Similarly, the major IFNL3/4 SNP haplotype rs8099917T-ss469415590TT-rs12979860C-rs4803217C (or T-TT-C-C) was a significant risk factor for lupus nephritis (P= 0.0015, OR 1.68, 95% CI 122-232). Additionally, all minor IFN3/4 SNP alleles were significantly associated with SLE susceptibility in nephritis-negative SLE patients as compared to normal healthy controls (rs8099917G, P-FDR = 0.00177, OR 1.68, 95% CI 124-2.28; rs12979860T, P-FDR = 0.00299, OR 1.58, 95% CI 1.18-2.32; rs4803217A, P-FDR = 0.00176, OR 1.65, 95% CI 1.22-223; and ss469415590 Delta G, P-FDR = 0.00176, OR 1.70, 95% CI 126-229). Furthermore, the elevated serum levels of IFN-lambda 3 were significantly correlated with the complement depression and the high SLE disease activities in SLE patients. Conclusions: IFN-lambda 3/4 genetic variants play a unique role in the development of lupus nephritis and SLE.
引用
收藏
页数:11
相关论文
共 49 条
[21]   Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses [J].
Hamming, Ole J. ;
Terczynska-Dyla, Ewa ;
Vieyres, Gabrielle ;
Dijkman, Ronald ;
Jorgensen, Sanne E. ;
Akhtar, Hashaam ;
Siupka, Piotr ;
Pietschmann, Thomas ;
Thiel, Volker ;
Hartmann, Rune .
EMBO JOURNAL, 2013, 32 (23) :3055-3065
[22]   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].
Hochberg, MC .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725
[23]   Interferon lambdas: the next cytokine storm [J].
Kelly, Christabel ;
Klenerman, Paul ;
Barnes, Eleanor .
GUT, 2011, 60 (09) :1284-1293
[24]   Selection on a Variant Associated with Improved Viral Clearance Drives Local, Adaptive Pseudogenization of Interferon Lambda 4 (IFNL4) [J].
Key, Felix M. ;
Peter, Benjamin ;
Dennis, Megan Y. ;
Huerta-Sanchez, Emilia ;
Tang, Wei ;
Prokunina-Olsson, Ludmila ;
Nielsen, Rasmus ;
Andres, Aida M. .
PLOS GENETICS, 2014, 10 (10)
[25]   Costimulatory Pathways: Physiology and Potential Therapeutic Manipulation in Systemic Lupus Erythematosus [J].
Kow, Nien Yee ;
Mak, Anselm .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2013,
[26]   Regulation of apoptosis by type III interferons [J].
Li, W. ;
Lewis-Antes, A. ;
Huang, J. ;
Balan, M. ;
Kotenko, S. V. .
CELL PROLIFERATION, 2008, 41 (06) :960-979
[27]   IFN-α Confers Resistance of Systemic Lupus Erythematosus Nephritis to Therapy in NZB/W F1 Mice [J].
Liu, Zheng ;
Bethunaickan, Ramalingam ;
Huang, Weiqing ;
Ramanujam, Meera ;
Madaio, Michael P. ;
Davidson, Anne .
JOURNAL OF IMMUNOLOGY, 2011, 187 (03) :1506-1513
[28]   Interferon-α Accelerates Murine Systemic Lupus Erythematosus in a T Cell-Dependent Manner [J].
Liu, Zheng ;
Bethunaickan, Ramalingam ;
Huang, Weiqing ;
Lodhi, Umairullah ;
Solano, Ingrid ;
Madaio, Michael P. ;
Davidson, Anne .
ARTHRITIS AND RHEUMATISM, 2011, 63 (01) :219-229
[29]   Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden [J].
Lu, Yi-Fan ;
Goldstein, David B. ;
Urban, Thomas J. ;
Bradrick, Shelton S. .
VIROLOGY, 2015, 476 :334-340
[30]   The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs [J].
McFarland, Addle P. ;
Horner, Stacy M. ;
Jarret, Abigail ;
Joslyn, Rochelle C. ;
Bindewald, Eckart ;
Shapiro, Bruce A. ;
Delker, Don A. ;
Hagedorn, Curt H. ;
Carrington, Mary ;
Gale, Michael, Jr. ;
Savan, Ram .
NATURE IMMUNOLOGY, 2014, 15 (01) :72-79